TY - JOUR
T1 - Nationwide Real-World Data of Microsatellite Instability and/or Mismatch Repair Deficiency in Cancer
T2 - Prevalence and Testing Patterns
AU - Fountzilas, Elena
AU - Papadopoulos, Theofanis
AU - Papadopoulou, Eirini
AU - Gouedard, Cedric
AU - Kourea, Helen P.
AU - Constantoulakis, Pantelis
AU - Magkou, Christina
AU - Sfakianaki, Maria
AU - Kotoula, Vassiliki
AU - Bantouna, Dimitra
AU - Raptou, Georgia
AU - Saetta, Angelica A.
AU - Christopoulou, Georgia
AU - Hatzibougias, Dimitris
AU - Michalopoulou-Manoloutsiou, Electra
AU - Siatra, Eleni
AU - Eleftheriadis, Eleftherios
AU - Kavoura, Evangelia
AU - Kaklamanis, Loukas
AU - Sourla, Antigoni
AU - Papaxoinis, George
AU - Pavlakis, Kitty
AU - Hytiroglou, Prodromos
AU - Vourlakou, Christina
AU - Arapantoni-Dadioti, Petroula
AU - Murray, Samuel
AU - Nasioulas, George
AU - Timologos, Grigorios
AU - Fountzilas, George
AU - Saridaki, Zacharenia
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/6
Y1 - 2024/6
N2 - Determination of microsatellite instability (MSI)/mismatch repair (MMR) status in cancer has several clinical implications. Our aim was to integrate MSI/MMR status from patients tested in Greece to assess the prevalence of MSI-high (MSI-H)/deficient MMR (dMMR) per tumor type, testing patterns over time and concordance between MSI and MMR status. We retrospectively recorded MSI/MMR testing data of patients with diverse tumor types performed in pathology and molecular diagnostics laboratories across Greece. Overall, 18 of 22 pathology and/or molecular diagnostics laboratories accepted our invitation to participate. In the 18 laboratories located across the country, 7916 tumor samples were evaluated for MSI/MMR status. MSI/MMR testing significantly increased in patients with colorectal cancer (CRC) and other tumor types overtime (p < 0.05). The highest prevalence was reported in endometrial cancer (47 of 225 patients, 20.9%). MSI-H/dMMR was observed in most tumor types, even in low proportions. Among 904 tumors assessed both for MSI and MMR status, 21 had discordant results (overall discordance rate, 2.3%). We reported MSI-H/dMMR prevalence rates in patients with diverse cancers, while demonstrating increasing referral patterns from medical oncologists in the country overtime. The anticipated high rate of concordance between MSI and MMR status in paired analysis was confirmed.
AB - Determination of microsatellite instability (MSI)/mismatch repair (MMR) status in cancer has several clinical implications. Our aim was to integrate MSI/MMR status from patients tested in Greece to assess the prevalence of MSI-high (MSI-H)/deficient MMR (dMMR) per tumor type, testing patterns over time and concordance between MSI and MMR status. We retrospectively recorded MSI/MMR testing data of patients with diverse tumor types performed in pathology and molecular diagnostics laboratories across Greece. Overall, 18 of 22 pathology and/or molecular diagnostics laboratories accepted our invitation to participate. In the 18 laboratories located across the country, 7916 tumor samples were evaluated for MSI/MMR status. MSI/MMR testing significantly increased in patients with colorectal cancer (CRC) and other tumor types overtime (p < 0.05). The highest prevalence was reported in endometrial cancer (47 of 225 patients, 20.9%). MSI-H/dMMR was observed in most tumor types, even in low proportions. Among 904 tumors assessed both for MSI and MMR status, 21 had discordant results (overall discordance rate, 2.3%). We reported MSI-H/dMMR prevalence rates in patients with diverse cancers, while demonstrating increasing referral patterns from medical oncologists in the country overtime. The anticipated high rate of concordance between MSI and MMR status in paired analysis was confirmed.
KW - Greece
KW - MMR
KW - MSI
KW - biomarker
KW - immunotherapy
KW - nationwide
KW - real-world data
UR - https://www.scopus.com/pages/publications/85196186440
U2 - 10.3390/diagnostics14111076
DO - 10.3390/diagnostics14111076
M3 - Article
AN - SCOPUS:85196186440
SN - 2075-4418
VL - 14
JO - Diagnostics
JF - Diagnostics
IS - 11
M1 - 1076
ER -